6 Podcast Episodes
Latest 7 Mar 2021 | Updated Daily
Novel daratumumab-based regimen slows multiple myeloma progression - Prof Antonio Palumbo
2016 ASCO Annual Meeting
Prof Palumbo presents at ASCO 2016, initial findings from a pivotal phase III trial that showed that daratumumab added to a standard two-drug regimen (bortezomib and dexamethasone) markedly improved outcomes for patients with recurrent or refractory multiple myeloma.
30 Jul 2016